Engineering the Human Microbiome Shows Promise for Treating Disease
By Justin L. Sonnenburg,
Scientific American
| 02. 17. 2015
Untitled Document
In the not too distant future each of us will be able to colonize our gut with genetically modified “smart” bacteria that detect and stamp out disease at the earliest possible moment. This scenario may sound like the premise for a sci-fi flick, but it is a very real possibility. Microbiome engineering holds great promise because of advances in the field of synthetic biology, which strives to create and rewire biological organisms so they perform desired tasks. Synthetic biologists are attempting to turn bacterial cells into the biological equivalent of the silicon wafer. These principles have been primarily applied to organisms for biofuel production, but the resulting techniques and genetic tool kit, when applied to our resident microbes, will have profound consequences for human health.
These resident microbes are adept at sensing what food is present, whether any pathogens are lurking and what the inflammatory state of the gut is—their survival depends on it. The model gut-resident bacterial species that we are using in our laboratory for initial tests, Bacteroides thetaiotaomicron, possesses more than 100 genetic circuits...
Related Articles
By Grace Won, KQED [with CGS' Katie Hasson] | 12.02.2025
In the U.S., it’s illegal to edit genes in human embryos with the intention of creating a genetically engineered baby. But according to the Wall Street Journal, Bay Area startups are focused on just that. It wouldn’t be the first...
Several recent Biopolitical Times posts (1, 2, 3, 4) have called attention to the alarmingly rapid commercialization of “designer baby” technologies: polygenic embryo screening (especially its use to purportedly screen for traits like intelligence), in vitro gametogenesis (lab-made eggs and sperm), and heritable genome editing (also termed embryo editing or reproductive gene editing). Those three, together with artificial wombs, have been dubbed the “Gattaca stack” by Brian Armstrong, CEO of the cryptocurrency company...
By Adam Feuerstein, Stat | 11.20.2025
The Food and Drug Administration was more than likely correct to reject Biohaven Pharmaceuticals’ treatment for spinocerebellar ataxia, a rare and debilitating neurodegenerative disease. At the very least, the decision announced Tuesday night was not a surprise to anyone paying attention. Approval...
By Lucy Tu, The Guardian | 11.05.2025
Beth Schafer lay in a hospital bed, bracing for the birth of her son. The first contractions rippled through her body before she felt remotely ready. She knew, with a mother’s pit-of-the-stomach intuition, that her baby was not ready either...